Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Allergic Bronchopulmonary Aspergillosis,...
Phase Not Applicable
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Fasenra — 30 Mg/mL Subcutaneous Solution

Primary Outcomes

  • Number of steroid requiring exacerbations (26 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-01
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Qianfoshan Hospital
Principal Investigators:
  • Qian Qi (STUDY_DIRECTOR) - Shandong First Medical University
Contact Information
Study Contact:
Qian Qi, Dr.
+86 13706380314
qiqianqlh@163.com
Qian Qi, Dr.
+86 13706380314
qiqianqlh@163.com
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
Qian Qi, Doctor
+86 13706380314
qiqianqlh@163.com
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University
Interventions
  • Drug: Fasenra — 30 Mg/mL Subcutaneous Solution
Study Locations (2 sites)
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong 250014 China
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong 250014 China
Eligibility Criteria
Inclusion Criteria: * Female and Male patients aged 18-75 years inclusively at the time of Visit 1 with a physician diagnosis of Allergic Bronchopulmonary Aspergillosis has met the ISHAM Working Group Diagnostic Criteria for ABPA: Predisposing condition: Bronchial asthma Obligatory criteria (both should be present) Type I aspergillus skin test positive (immediate cutaneous hypersensitivity Aspergillus antigen) or elevated IgE level against Aspergillus fumigatus (Af) Aspergillus niger or Aspergillus flavus may be eligible provided antigen-specific IgE and IgG measurements are available for use. Elevated total IgE levels (\>1,000IU/mL)\* Other criteria (at least two of three) Presence of precipitating or IgG antibodies against Af in serum Radiographic pulmonary opacities consistent with ABPA Total eosinophil count \>500 cells/uL in steroid naïve patients (may be historical) (if the patient meets all other criteria, an IgE value \<1,000 IU/mL may be acceptable) Severe chronic asthma (for at least 12 months) requiring treatment with high dose ICS plus asthma controller prior to Visit 1 Other acceptable asthma controllers include long acting bronchodilators (e.g. a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), a leukotriene inhibitor, theophylline preparations and/or maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control Documented current treatment with high daily doses of ICS ( \>500ug of FP equivalent) plus at least one other asthma controller for at least 3 months prior to Visit 1 For ICS/LABA combination preparation, highest-strength maintenance doses approved in the U.S. will meet this criterion If the ICS and the other asthma controller therapies are given by separate inhalers, then the patient must be on a high daily ICS dose for 3 months prior to entering the study. History of at least 2 asthma exacerbations while on ICS plus another asthma controller (see inclusion criterion 2 for examples) that required treatment with systemic corticosteroids (IM, IV, or oral) in the 12 months prior to Visit 1. For patients receiving oral corticosteroids as a maintenance therapy, an exacerbation is defined as a temporary increase of their maintenance dose for a minimum of 3 days. Weight \> 40kg Exclusion Criteria: * Clinical important pulmonary disease other than asthma with allergic bronchopulmonary aspergillosis (ie. chronic obstructive pulmonary disease (COPD), cystic fibrosis, sarcoid, and pulmonary fibrosis) History of anaphylaxis to any biologic therapy Known history of allergy or hypersensitivity reaction to benralizumab or any of its components Current smokers or former smokers with a smoking history of \> 10 pack years. A former smoker is defined as a patient who quit smoking at least 6 months prior to Visit 1. Currently pregnant, breastfeeding, or lactating women Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational.
Conditions Major Depressive Disorder (MDD)
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Against the clinical backdrop of the growing global burden of neuropsychiatric disorders, the rapid rise in depression prevalence, and the frequent association of these conditions with cognitive impairment, this study highlights the limitations of current cognitive assessment tools-such as their time-consuming nature and lack of specificity-and underscores the urgent need to develop simple and efficient assessment methods. In terms of treatment, modified electroconvulsive therapy (ECT) and magnetic seizure therapy (MST) are rapidly acting neuromodulation therapies; however, their effects on cognitive function and underlying brain mechanisms remain controversial, and there is a lack of direct comparative studies. Functional near-infrared spectroscopy (fNIRS) technology can non-invasively monitor changes in cerebral hemodynamics, providing a powerful tool for assessing brain function before and after treatment. Therefore, this study aims to combine resting-state and task-based fNIRS with multidimensional cognitive and emotional assessments to systematically compare the effects of ECT and MST on frontal-temporal cerebral hemodynamics. We seek to clarify the differences in brain function regulation between the two treatment modalities and their association with improvements in cognition and mood, with the goal of providing scientific evidence to elucidate the brain mechanisms underlying neurostimulation therapies and optimize individualized treatment plans.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Electroconvulsive Therapy — Electroconvulsive therapy will be administered 2 to 3 times per week according to a standardized protocol. Stimulation parameters-including intensity, target site, number of sessions, and duration-will be individually tailored for each participant based on prior research to ensure targeted and safe delivery within established safety parameters. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.
  • Other: Magnetic Seizure Therapy — Magnetic seizure therapy will be administered 2 to 3 times per week according to a standardized protocol. Stimulation parameters-including intensity, target location, number of sessions, and duration-will be individually tailored for each participant based on prior research to ensure targeted and safe delivery within established safety parameters. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.

Primary Outcomes

  • Change in Hamilton Depression Rating Scale (HAMD) Score (baseline and immediately after the intervention)
  • Differences in frontal and temporal lobe function during cognitive tasks in patients with depression following seizure therapy. (baseline and immediately after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-30
Completion: 2029-04-30
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Second Hospital of Anhui Medical University
Contact Information
Study Contact:
Yanghua Tian
+86-13955188448
tianyh@ahmu.edu.cn
Nanxue Duan
+86-18326962052
791909941@qq.com
The Second Affiliated Hospital of Anhui Medical University
Interventions
  • Other: Electroconvulsive Therapy — Electroconvulsive therapy will be administered 2 to 3 times per week according to a standardized protocol. Stimulation parameters-including intensity, target site, number of sessions, and duration-will be individually tailored for each participant based on prior research to ensure targeted and safe delivery within established safety parameters. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.
  • Other: Magnetic Seizure Therapy — Magnetic seizure therapy will be administered 2 to 3 times per week according to a standardized protocol. Stimulation parameters-including intensity, target location, number of sessions, and duration-will be individually tailored for each participant based on prior research to ensure targeted and safe delivery within established safety parameters. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.
Study Locations (1 sites)
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601 China
Eligibility Criteria
Inclusion Criteria: * A depressive episode diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by two psychiatrists; * Meets the treatment criteria for ECT or MST; * At least 5 years of education, with no significant hearing or visual impairments; * Voluntary participation in this study, with a signed written informed consent form, and willingness to cooperate with the collection of general demographic information, neuropsychological testing, and fNIRS resting-state and task-based data acquisition. Exclusion Criteria: * Co-occurring mental disorders (such as substance use disorders or schizoaffective disorder); * Severe physical illness; * History of neurological disorders (such as traumatic brain injury or dementia); * Low educational attainment; * Receipt of ECT or MST treatment within the past six months.
Conditions Spinal Cord Injury, Orthostatic Hyperten...
Phase NA
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if non-invasive spinal cord stimulation intervention improves blood pressure regulation in individuals with chronic spinal cord injury. The main questions it aims to answer are: * Can site specific spinal cord stimulation enhance blood pressure regulation? * Does this stimulation affect enzymes responsible for blood pressure regulation? Researchers will stimulate different sites of spinal cord and compare to see if site-specific stimulation provide blood pressure stability. Participants will have up to six pairs of self-adhesive conductive electrodes placed on the skin over the spinal cord (midline and/or just to the left and right of midline) as cathodes and up to six pairs of self-adhesive electrodes located symmetrically on the skin over the iliac crests, clavicles, shoulders, and/or abdominal muscles (left and right of the umbilicus) as anodes for stimulation of the spinal cord.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Spinal Cord Transcutaneous Stimulation — Spinal Cord Transcutaneous Stimulation (scTS) will be administered using the Biostim/Neostim (Cosyma Inc., Denver CO) device. Up to six pairs of self-adhesive conductive electrodes will be placed on the skin over the spinal cord (midline and/or just to the left and right of midline) as cathodes and up to six pairs of self-adhesive electrodes located symmetrically on the skin over the iliac crests, clavicles, shoulders, and/or abdominal muscles (left and right of the umbilicus) as anodes. During scTS mapping sessions, stimulation will be provided to assess the impact on functional outcomes and to refine stimulation parameters for training (e.g., blood pressure modulation, respiratory function) targeted for each arm. Using multi-variant combinations of electrode locations and different electrical configurations, the stimulation will be delivered at a level specific to each arm with frequency of up to 100 Hz, with incrementally increased intensity up to 200 mA.

Primary Outcomes

  • Baroreflex Sensitivity (Within 4 weeks before an intervention; within 2 weeks after intervention #40; within 2 weeks after intervention #80; within 2 weeks after weeks after 8 weeks and 16-weeks follow-up period.)
  • Renal Artery Systolic Velocity (Right and Left) (Within 4 weeks before an intervention; within 2 weeks after intervention #40; within 2 weeks after intervention #80; within 2 weeks after weeks after 8 weeks and 16-weeks follow-up period.)
  • Plasma Renin Activity (Within 4 weeks before an intervention; within 2 weeks after intervention #20; within 2 weeks after intervention #40; within 2 weeks after intervention #60; within 2 weeks after intervention #80; within 2 weeks after weeks after 8 and 16-weeks follow-up.)
  • Angiotensin Converting Enzyme (Within 4 weeks before an intervention; within 2 weeks after intervention #20; within 2 weeks after intervention #40; within 2 weeks after intervention #60; within 2 weeks after intervention #80; within 2 weeks after weeks after 8 and 16-weeks follow-up.)
  • Aldosterone (Within 4 weeks before an intervention; within 2 weeks after intervention #20; within 2 weeks after intervention #40; within 2 weeks after intervention #60; within 2 weeks after intervention #80; within 2 weeks after weeks after 8 and 16-weeks follow-up.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2029-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Louisville
Collaborators: Kentucky Spinal Cord and Head Injury Research Board
Principal Investigators:
  • Alexander Ovechkin (PRINCIPAL_INVESTIGATOR) - University of Louisville
Contact Information
Study Contact:
Andrea M Willhite
1-502-581-8675
andrea.willhite@louisville.edu
Kristin Benton
1-502-581-8675
kristin.benton@louisville.edu
Andrea M Willhite
502-582-8675
andrea.willhite@louisville.edu
Frazier Rehabilitation and Neuroscience Institute
Interventions
  • Device: Spinal Cord Transcutaneous Stimulation — Spinal Cord Transcutaneous Stimulation (scTS) will be administered using the Biostim/Neostim (Cosyma Inc., Denver CO) device. Up to six pairs of self-adhesive conductive electrodes will be placed on the skin over the spinal cord (midline and/or just to the left and right of midline) as cathodes and up to six pairs of self-adhesive electrodes located symmetrically on the skin over the iliac crests, clavicles, shoulders, and/or abdominal muscles (left and right of the umbilicus) as anodes. During scTS mapping sessions, stimulation will be provided to assess the impact on functional outcomes and to refine stimulation parameters for training (e.g., blood pressure modulation, respiratory function) targeted for each arm. Using multi-variant combinations of electrode locations and different electrical configurations, the stimulation will be delivered at a level specific to each arm with frequency of up to 100 Hz, with incrementally increased intensity up to 200 mA.
Study Locations (2 sites)
Frazier Rehabilitation and Neuroscience Institute, Louisville, Kentucky 40202 United States
Frazier Rehabilitation Institute, Louisville, Kentucky 40202 United States
Eligibility Criteria
Inclusion Criteria: * At least 18 years old, * Stable medical condition, * Non-progression SCI (no negative change in the neurological level and motor-completeness assess during screening when compared to the neurological status assessed at 6-month period after injury or at least 6 months prior to the screening), * Motor-complete SCI according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade "A," "B," or "C" above T1 spinal level according to the ASIA International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Neurological Level of Injury (NLI), * Sustained SCI at least 12 months prior to entering the study, * Evidence of symptomatic hypotension as determined by a total score \>0 on the Orthostatic Hypotension Symptom Assessment (OSHA), * Normal renal function as defined by eGFR \> 59 ml/min/1.73, creatinine value within the range of 0.6-1.2 mg/dl, and BUN values within the range of 7-18 mg/dl, * Competent to give informed consent for the research protocol, * Able to understand instructions. Exclusion Criteria: * Major pulmonary or cardiovascular disease unrelated to SCI, * Ventilator dependence, * Painful musculoskeletal dysfunction that might interfere with testing or stimulation, * Unhealed fracture that might interfere with testing or stimulation, * Unhealed contracture that might interfere with testing or stimulation, * Unhealed pressure sore that might interfere with testing or stimulation, * Untreated clinically significant depression or psychiatric disorders, * Ongoing drug abuse, * Malignancy , * Class III obesity (BMI \>40) and at least one co-morbidity thereof: a) Type 2 diabetes as defined by ≥6.5% level on two separate glycated hemoglobin (A1C) tests, b) hypertension as defined by consistent blood pressure readings of ≥140/90 mmHg or taking medication for blood pressure, * Acute or chronic obstructive deep vein thrombosis, * Secondary hypotension unrelated to SCI (anemia, hypervolemia, endocrine and neurological diseases), * Major esophageal/gastrointestinal problem, * Currently pregnant (females of childbearing potential only), * Other major medical illness contraindicated for testing or stimulation.

Diabetes Body Project 2

NCT07468188
Recruiting
Conditions Eating Disorders, Type 2 Diabetes
Phase NA
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to test the feasibility and effectiveness of an eating disorder prevention program specifically targeted for women with type 2 diabetes (T2D) called the Diabetes Body Project 2 (DBP2). The Diabetes Body Project 2 (DBP2) will be adapted from the Diabetes Body Project, which is an eating disorder prevention program developed to improve satisfaction with body image and diabetes management for young women with type 1 diabetes (DBP). The study is looking to see if the DBP is effective in improving body image concerns, reducing disordered eating behaviors and improving glycemic control in women with T2D.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Body Project Type 2 — This program consists of weekly 1-hour sessions for 6 weeks, co-led by 2 facilitators. Each session has home exercises. Home exercises are discussed at each session. session 1, collectively define the thin appearance ideal, discuss costs of pursuing this ideal. session 2 dissuade facilitators from pursuing the thin ideal in role-plays. session 3, conduct role-plays challenging thin-ideal statements, discuss personal body image concerns. session 4, the negative effects of social comparison, the advantages and costs of social media. session 5, strategies of living well with diabetes and maintaining good self-care, as well as the physiological and psychological advantages of insulin. session 6 discuss the benefits of the group and what was learned and how to continue some of the exercises introduced in the Diabetes Body Project; participants are encouraged to engage in at least one more self-affirmation exercise and email the facilitators to tell them how it went.

Primary Outcomes

  • Intervention refinement (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-24
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Joslin Diabetes Center
Contact Information
Study Contact:
Christine Slyne
6173094683
christine.slyne@joslin.harvard.edu
Molly Savory
6173091997
msavory1@joslin.harvard.edu
Christine Slyne
6173094683
Joslin Diabetes Center
Interventions
  • Behavioral: Body Project Type 2 — This program consists of weekly 1-hour sessions for 6 weeks, co-led by 2 facilitators. Each session has home exercises. Home exercises are discussed at each session. session 1, collectively define the thin appearance ideal, discuss costs of pursuing this ideal. session 2 dissuade facilitators from pursuing the thin ideal in role-plays. session 3, conduct role-plays challenging thin-ideal statements, discuss personal body image concerns. session 4, the negative effects of social comparison, the advantages and costs of social media. session 5, strategies of living well with diabetes and maintaining good self-care, as well as the physiological and psychological advantages of insulin. session 6 discuss the benefits of the group and what was learned and how to continue some of the exercises introduced in the Diabetes Body Project; participants are encouraged to engage in at least one more self-affirmation exercise and email the facilitators to tell them how it went.
Study Locations (1 sites)
Joslin Diabetes Center, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: * 1.) Female sex 2) self-reported gender identity of "woman"; 3) age 18-40 years old; 4) diagnosed with T2D for at least 6 months; 5) experiencing at least one body image concern. Exclusion Criteria: * Recent hospitalization for eating disorder within the last 12 months * Eating disorder related diabetic ketoacidosis within the last 12 months * unwillingness to be video-recorded, * restricted English proficiency * developmental, cognitive, or psychiatric limitations that compromise participation in the intervention sessions and study.
Conditions Large Airway Collapse, Asthma
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Large airway collapse (LAC) is an increasingly recognised condition characterised by either bowing of the posterior membrane/trachealis muscle into the trachea or main bronchi (also known as excessive dynamic airway collapse, EDAC) or weakening of the tracheal cartilage (also known as tracheobronchomalacia, TBM).(1-3) LAC often co-exists with other chronic airway conditions, such as asthma or chronic obstructive pulmonary disease (COPD) and is frequently misdiagnosed or overlooked as symptoms, such as shortness of breath, cough and wheeze overlap with other respiratory disease.(1) There is no standardised treatment pathway for patients diagnosed with LAC and current treatment options are limited to physiotherapy and/or hypertonic saline.(3) Exacerbations of LAC, defined as an acute worsening of respiratory symptoms, typically reduce health-related quality of life and increase healthcare utilisation.(4) Small studies and case series have suggested continuous positive airway pressure (CPAP) as a potential treatment for LAC to reduce exacerbations and improve quality of life.(5,6) It is hypothesised CPAP may work as a pneumatic splint helping to prevent dynamic collapse of the large airways. This may increase lung volumes due to increase in flow at functional residual capacity (FRC) and support higher elastic recoil and increased expiratory flow. Additionally, splinting of the large airways may cause stiffening of the large airways, resulting in less resistance and turbulence during expiration and may support sputum expectoration.(3) There is a need for high quality randomised controlled trial (RCT) evidence to inform clinical recommendations in the United Kingdom (UK), as well as globally. Prior to this there is a need for further work exploring the feasibility of performing a large RCT and understanding the acceptability of CPAP as a future treatment for LAC. Aim To conduct a randomised feasibility study that will provide data to confirm if a larger randomised trial of CPAP in patients diagnosed with LAC is viable

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: CPAP — Nocturnal CPAP

Primary Outcomes

  • Patient acceptability (From Enrolment until 1 year)
  • Recruitment and Retention (At 18 months post enrolment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-20
Completion: 2028-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Liverpool School of Tropical Medicine
Collaborators: Royal Liverpool University Hospital
Contact Information
Study Contact:
Rebecca Nightingale Dr Nightingale, PhD
+441517053100
rebecca.nightingale@lstmed.ac.uk
Rachel Burton Dr Burton, MD
+441517053100
rachel.burton@lstmed.ac.uk
Rachel Burton, MD
01517062000
rachel.burton@liverpoolft.nhs.uk
The Royal Liverpool Hospital
Interventions
  • Device: CPAP — Nocturnal CPAP
Study Locations (1 sites)
The Royal Liverpool Hospital, Liverpool, United Kingdom
Eligibility Criteria
Inclusion Criteria 1. Adult (≥18 years) at visit 1 2. Able to provide informed consent 3. Prior confirmation of LAC (diagnosed either radiographically or with bronchoscopy) 4. Respiratory co-morbidities optimised 5. ≥1 course of antibiotics and/or prednisolone for an exacerbation of chronic airway disease in the preceding 12 months before visit 1. Exclusion Criteria 1. Contraindication to CPAP as per British Thoracic Society (BTS) guidelines 2. Already using domiciliary CPAP (including privately purchased) 3. Known obstructive sleep apnoea syndrome (OSAS) eligible for CPAP 4. Suspected OSAS that is awaiting further investigation 5. Pregnant or planning a pregnancy in the next 12 months

Allopurinol in Depression

NCT07574060
Recruiting
Conditions Depression
Phase PHASE2, PHASE3
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Sertraline 50 MG — Sertraline is an antidepressant medication of the selective serotonin reuptake inhibitor class used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder.
  • Drug: Allopurinol 300 MG — Allopurinol is a potent inhibitor of the enzyme xanthine oxidase and is primarily used to treat hyperuricemia and gout

Primary Outcomes

  • Change in the 17-item Ham-D depression score. (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2026-05-20
Completion: 2027-05-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tanta University
Contact Information
Study Contact:
Mostafa M I Bahaa, PhD
0201025538337
mbahaa@horus.edu.eg
Tanta Unuversity
Mostafa M Bahaa, PhD
Tanta Unuversity
Interventions
  • Drug: Sertraline 50 MG — Sertraline is an antidepressant medication of the selective serotonin reuptake inhibitor class used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder.
  • Drug: Allopurinol 300 MG — Allopurinol is a potent inhibitor of the enzyme xanthine oxidase and is primarily used to treat hyperuricemia and gout
Study Locations (1 sites)
Tanta Unuversity, Tanta, 31527 Egypt
Eligibility Criteria
Inclusion Criteria: Patients aged greater than 18 years old. Patients with a HAM-D score of at least 10 with item 1, depressed mood, scoring 2 or greater, are eligible. Exclusion Criteria: Patients with bipolar I or bipolar II disorder Patients with eating disorders Pregnant women or women not using medically accepted means of birth control Cardiovascular disorders Severe renal impairment
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to develop the Active Health Behavior Scale for Type 2 Diabetes Mellitus (T2DM) patients and evaluate its psychometric properties, including internal consistency reliability, test-retest reliability, content validity, construct validity, and criterion-related validity. Additionally, this research will investigate the current status of active health behaviors among T2DM patients and employ latent profile analysis (LPA) to identify distinct behavioral subtypes. Furthermore, differences in demographic, clinical, and psychosocial determinants across the identified latent classes will be examined to inform tailored intervention strategies.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Cross-sectional Study — In phase I, face-to-face semi-structured interviews will be conducted with approximately 15 patients with T2DM and 15 relevant healthcare workers (clinicians and nurses) from the Department of Endocrinology and Metabolism at the Third Affiliated Hospital of Soochow University. Each interview will last 15-30 minutes and take place in a quiet setting, such as an inpatient ward or demonstration classroom. In phase II (scale validation) and phase III (survey), T2DM patients attending the same department will be recruited.

Primary Outcomes

  • Total scale score of the Active Health Behavior Scale for Patients with Type 2 Diabetes Mellitus. (One year, from December 2025 to December 2026)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-24
Completion: 2027-02-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yun Ye
Contact Information
Study Contact:
Yun Ye
0519-68870000
ntyeyun@163.com
Yun Ye
0519-68870000
ntyeyun@163.com
The Third Affiliated Hospital of Soochow University(THE FIRST PEOPLE'S HOSPITAL OF CHANGZHOU)
Interventions
  • Other: Cross-sectional Study — In phase I, face-to-face semi-structured interviews will be conducted with approximately 15 patients with T2DM and 15 relevant healthcare workers (clinicians and nurses) from the Department of Endocrinology and Metabolism at the Third Affiliated Hospital of Soochow University. Each interview will last 15-30 minutes and take place in a quiet setting, such as an inpatient ward or demonstration classroom. In phase II (scale validation) and phase III (survey), T2DM patients attending the same department will be recruited.
Study Locations (1 sites)
The Third Affiliated Hospital of Soochow University(THE FIRST PEOPLE'S HOSPITAL OF CHANGZHOU), Changzhou, Jiangsu 213000 China
Eligibility Criteria
Inclusion Criteria: * Patients with T2DM 1. Who have been diagnosed with T2DM and meet the diagnostic criteria defined by the Chinese Guideline for the Prevention and Treatment of Diabetes (2024 Edition); 2. Aged ≥18 years; 3. Who volunteer to participate in this study. Healthcare workers: 1. Clinicians and nurses who have been engaged in medical care in the endocrine field for ≥5 years; 2. Who hold a Bachelor's degree or above and have an intermediate or above professional title. Exclusion Criteria: * Patients with T2DM: 1. Who have acute complications of T2DM or other serious life-threatening diseases that preclude cooperation with the study; 2. Who have cognitive impairment or are unable to communicate in writing or verbally Healthcare workers: 1. Who do not have direct contact with patients; 2. Who are currently undergoing standardized training or refresher programs.
Conditions Mild Cognitive Impairment (MCI), Dementi...
Phase Not Applicable
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn how daily emotional stress affects cognitive function and inflammation in community-dwelling older adults aged 60 and older in Seoul, Republic of Korea. The main questions it aims to answer are: Does daily psychological stress measured in real-time affect short-term and long-term cognitive function in older adults? Do pro-inflammatory cytokines (such as CRP, IL-6, IL-10, and TNF-α) mediate the relationship between emotional stress and cognitive decline? How do social support and social isolation influence cognitive function and inflammatory biomarkers over time? Participants will: Complete baseline surveys assessing depression, cognitive function, and personal characteristics Use a smartphone app to answer brief surveys about their emotions, cognitive performance, and social interactions 1-6 times daily for two weeks Wear a Galaxy Watch to track sleep quality, heart rate, and physical activity Provide blood samples for inflammatory biomarker analysis Return for follow-up assessments at 6 months and 1 year This study is part of an international collaboration to establish a Korean cohort comparable to the U.S. Einstein Aging Study, with the aim of developing culturally tailored dementia prevention strategies.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Incident MCI and Dementia Diagnosis (baseline, 6-month, 1-year, 5-year and 10-year follow-up)
  • SNSB-2 Composite Score (Baseline and 12 months)
  • Wechsler Memory Scale Score (Baseline, 6 months, and 12 months)
  • Block Design Subtest Score (Baseline, 6 months, and 12 months)
  • EMA Daily Cognitive Task Performance (Daily during 2-week EMA period at baseline, 6 months, and 12 months)
  • Plasma Phosphorylated Tau (p-tau) Level (Baseline, 6 months, and 12 months)
  • Pro-Inflammatory Cytokine Composite Score (Baseline, 6 months, and 12 months)
  • Plasma Amyloid Beta (Aβ) Level (Baseline, 6 months, and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-01
Completion: 2037-12-31
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Korea University
Collaborators: Korea University Anam Hospital, Penn State University, Albert Einstein College of Medicine
Principal Investigators:
  • Sunmi Song (PRINCIPAL_INVESTIGATOR) - Korea University
Contact Information
Study Contact:
Sunmi Song, PhD
+82232904439
sunmi.song0715@gmail.com
Sunmi Song
01087489593
sunmi.song0715@gmail.com
Korea University
Interventions
N/A
Study Locations (1 sites)
Korea University, Seoul, Select One... 02841 South Korea
Eligibility Criteria
Inclusion Criteria: * Adults aged 60 or older residing in the Republic of Korea * Samsung Galaxy smartphone users capable of using smartphone applications * Sufficient cognitive ability to understand and follow research instructions (MMSE score of 21 or above) * For individuals who do not meet the cognitive criteria, those who understand the study procedures and provide informed consent along with their legal guardian Exclusion Criteria: * Diagnosis of dementia at baseline * Severe visual or hearing impairments that prevent participation in psychological assessments * Illiteracy that prevents participation in cognitive testing * Less than 80% compliance with the 2-day preliminary EMA protocol (one additional attempt allowed after re-training) * Current alcohol or substance abuse * Inability to ambulate or psychiatric conditions that prevent survey participation * Currently undergoing cancer treatment or received chemotherapy within the past 6 months
Conditions Obesity, Diabetes Mellitus, Type 2
Phase PHASE4
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective cohort study evaluating the efficacy, safety, and tolerability of tirzepatide under real-world conditions in the Paraguayan population. The study includes two cohorts: Cohort 1 consists of adults with obesity (BMI ≥30 kg/m²) without type 2 diabetes mellitus (T2DM), and Cohort 2 consists of adults with T2DM with or without obesity. Each cohort will enroll 80 participants (160 total). All participants will receive tirzepatide as part of their standard clinical care and will be followed for 52 weeks with visits approximately every 6 weeks. Primary outcomes include percentage change in body weight from baseline at week 52 (Cohort 1) and change in HbA1c and body weight at week 52 (Cohort 2). Safety outcomes include adverse event rates. The study is conducted at Las Rias Medical Center, Asuncion, Paraguay, and has been approved by the CEI-INCAN Ethics Committee and authorized by DINAVISA.

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.) — Participants will receive subcutaneous injections of tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.) once weekly. The dosage will be adjusted according to standard clinical practice and the investigator's discretion, following the manufacturer's titration schedule (starting at 2.5 mg and increasing up to 15 mg as tolerated).

Primary Outcomes

  • Mean Percent Change From Baseline in Body Weight at 52 Weeks. (Baseline and 52 weeks.)
  • Mean Change From Baseline in Glycated Hemoglobin (HbA1c) at 52 Weeks. (Baseline and 52 weeks.)
  • Number of Participants With Treatment-Emergent Adverse Events (TEAEs). (Through week 52.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-07-27
Completion: 2027-08-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Las Rías Medical Center
Collaborators: LABORATORIO DE PRODUCTOS ETICOS C.E.I.S.A
Principal Investigators:
  • ELIZABETH VALINOTTI DELMAS, MD (PRINCIPAL_INVESTIGATOR) - LAS RIAS MEDICAL CENTER
Contact Information
Study Contact:
ELIZABETH VALINOTTI DELMAS, MD
+595 981 312 888
elizabeth.valinotti@lasrias.com.py
Sandra Soto Valiente
smsv81@gmail.com
Elizabeth Valinotti Delmás, MD
595981312888
elizabeth.valinotti@lasrias.com.py
Centro Médico Las Rias
Interventions
  • Drug: Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.) — Participants will receive subcutaneous injections of tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.) once weekly. The dosage will be adjusted according to standard clinical practice and the investigator's discretion, following the manufacturer's titration schedule (starting at 2.5 mg and increasing up to 15 mg as tolerated).
Study Locations (1 sites)
Centro Médico Las Rias, Asunción, Paraguay
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 70 years at the time of informed consent. * Stable residence in Paraguay for at least 12 months prior to screening. * Ability to provide written informed consent and comply with all study procedures. * Sufficient proficiency in the Spanish language to complete questionnaires and follow study instructions. * Clinical stability, defined as the absence of hospitalization related to diabetes or obesity complications within 3 months prior to screening. * Adequate renal function, defined as an estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73m² calculated using the CKD-EPI equation. * For participants enrolled in the obesity cohort: clinical diagnosis of obesity with BMI ≥30 kg/m², no prior diagnosis of diabetes mellitus (HbA1c \<6.5%), and at least one documented unsuccessful attempt at dietary weight-loss intervention within the previous 12 months. * For participants enrolled in the type 2 diabetes mellitus (T2DM) cohort: established diagnosis of T2DM for at least 6 months prior to screening according to ADA 2025 criteria, HbA1c between 7.0% and 9.5% at screening confirmed at baseline, BMI ≥24 kg/m², and stable treatment on monotherapy or dual therapy with metformin, sulfonylureas, DPP-4 inhibitors, or SGLT-2 inhibitors for at least 3 months prior to screening. Exclusion Criteria: * Diagnosis of type 1 diabetes mellitus or secondary causes of diabetes. * History of diabetic ketoacidosis within 12 months prior to screening. * Current or recent use (within 3 months prior to screening) of GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists. * Current or prior use of insulin therapy for the management of diabetes. * Clinically significant untreated thyroid dysfunction, including hypothyroidism or hyperthyroidism. * Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. * Major adverse cardiovascular event (MACE), including acute myocardial infarction, stroke, or hospitalization for heart failure within 6 months prior to screening. * Heart failure classified as New York Heart Association (NYHA) Functional Class III or IV. * Uncontrolled hypertension, defined as systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg despite optimal antihypertensive therapy. * History of acute or chronic pancreatitis. * Active inflammatory bowel disease or prior bariatric surgery. * Clinically significant diabetic gastroparesis or other gastrointestinal motility disorders that may interfere with the absorption of concomitant oral medications. * Use of systemic corticosteroids for more than 14 consecutive days within 3 months prior to screening. * Treatment with oral anti-obesity medications (including orlistat, phentermine, naltrexone/bupropion, or topiramate) within 3 months prior to screening. * Participation in another clinical trial involving an investigational medicinal product within 30 days prior to screening. * Moderate to advanced chronic kidney disease defined as eGFR \<45 mL/min/1.73m² or requirement for dialysis. * Active liver disease or transaminase levels (ALT/AST) greater than 3 times the upper limit of normal. * Active malignancy or history of cancer within the previous 5 years, except for completely resected basal cell or squamous cell skin carcinoma. * Uncontrolled major psychiatric disorders or history of suicide attempt within the previous 2 years. * Confirmed or suspected pregnancy, including positive serum beta-hCG test at screening, or active breastfeeding. * Intention to become pregnant during the study period. * Women of childbearing potential unwilling to use effective contraceptive methods (hormonal, intrauterine, or dual-barrier) throughout the study and for 3 months after the final dose.
Conditions Cirrhosis, Esophageal and Gastric Varice...
Phase PHASE4
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing portal hypertension-related complications in patients with cirrhosis. Conducted at the Gastroenterology and Hepatology Department and Clinical Trials Unit (CTU) of Asian Institute of Medical Sciences (AIMS) Hospital, Hyderabad, Pakistan, the trial will enroll eligible cirrhotic patients with portal hypertension. Participants will be followed for 12 months to monitor hepatic decompensation events, variceal bleeding, portal vein thrombosis, and mortality, while safety and tolerability of apixaban will be closely assessed. This study aims to provide local evidence for apixaban use in cirrhosis management in Pakistan.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Drug: Apixaban — Apixaban 2.5 mg oral tablet taken twice daily for 12 months. Apixaban is a direct factor Xa inhibitor that blocks thrombin generation and clot formation through inhibition of the coagulation cascade. Dose adjustment: continue 2.5 mg twice daily if eGFR ≥30 mL/min/1.73 m²; if eGFR 15-29 mL/min/1.73 m², continue with close monitoring; if eGFR \<15 mL/min/1.73 m², discontinue. Withheld in case of major bleeding or severe hepatic decompensation.
  • Drug: Carvedilol — Carvedilol oral tablet titrated according to protocol-defined schedule. Initiated at 6.25 mg once daily at baseline. Titrated every 2-4 weeks based on heart rate and blood pressure: 6.25 mg twice daily at week 2, 12.5 mg twice daily at week 4, with target maintenance dose of 12.5 mg twice daily. Dose may be reduced or withheld if heart rate \<55 bpm, systolic blood pressure \<90 mmHg, or symptomatic hypotension develops.
  • Drug: Placebo — Placebo oral tablet matching apixaban in appearance, taken twice daily for 12 months. No active ingredient.

Primary Outcomes

  • First Occurrence of Portal Hypertension-Related Complications (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-04-01
Completion: 2028-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Asian Institute Of Medical Sciences
Principal Investigators:
  • Sadik Memon, MBBS,MRCP,FCPS (PRINCIPAL_INVESTIGATOR) - Asian Institute Of Medical Sciences
  • Dr. Fatima Nadeem, Pharm-D, Mphil (STUDY_DIRECTOR) - Asian Institute Of Medical Sciences
Contact Information
Study Contact:
Fatima Nadeem Dr, Pharm-D, Mphil
+923080744996
fatima.nadeem2401@gmail.com
Dr Fatima
03080744996
fatima.nadeem229@amalacademy.org
Asian Institute of Medical Sciences
sadikmemon@gmail.com
Asian Institute of Medical Sciences
Interventions
  • Drug: Apixaban — Apixaban 2.5 mg oral tablet taken twice daily for 12 months. Apixaban is a direct factor Xa inhibitor that blocks thrombin generation and clot formation through inhibition of the coagulation cascade. Dose adjustment: continue 2.5 mg twice daily if eGFR ≥30 mL/min/1.73 m²; if eGFR 15-29 mL/min/1.73 m², continue with close monitoring; if eGFR \<15 mL/min/1.73 m², discontinue. Withheld in case of major bleeding or severe hepatic decompensation.
  • Drug: Carvedilol — Carvedilol oral tablet titrated according to protocol-defined schedule. Initiated at 6.25 mg once daily at baseline. Titrated every 2-4 weeks based on heart rate and blood pressure: 6.25 mg twice daily at week 2, 12.5 mg twice daily at week 4, with target maintenance dose of 12.5 mg twice daily. Dose may be reduced or withheld if heart rate \<55 bpm, systolic blood pressure \<90 mmHg, or symptomatic hypotension develops.
  • Drug: Placebo — Placebo oral tablet matching apixaban in appearance, taken twice daily for 12 months. No active ingredient.
Study Locations (1 sites)
Asian Institute of Medical Sciences, Hyderābād, Sindh 71000 Pakistan
Eligibility Criteria
Inclusion Criteria: 1. Adults aged ≥18 years with diagnosed cirrhosis (any etiology), confirmed by histology, transient elastography (≥12.5 kPa), or consistent clinical/imaging findings. 2. Evidence of portal hypertension, defined by: Clinical: presence of varices on endoscopy, ascites, or splenomegaly with thrombocytopenia. 3. Compensated or early decompensated cirrhosis (Child-Pugh B 7-10), with stable liver function defined as no change in Child-Pugh score \>1 point in the preceding 3 months. 4. Screening esophagogastroduodenoscopy (EGD) performed within 6 months prior to enrollment. Patients with high-risk varices (large varices, red wale signs, or history of variceal bleeding) must undergo endoscopic variceal band ligation to obliteration before randomization. 5. Able to provide informed consent and comply with study procedures. Exclusion Criteria: 1. Active gastrointestinal bleeding within 6 weeks prior to enrollment. 2. High bleeding risk: * Platelet count \<50,000/µL at baseline * INR \>1.8 (or \>2.0 if secondary to cirrhosis without additional coagulopathy) * Active peptic ulcer disease * History of intracranial hemorrhage or hemorrhagic stroke * Known bleeding diathesis 3. Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) or on dialysis. 4. Child-Pugh class C or Child-Pugh score ≥10. 5. History of hypersensitivity to apixaban or carvedilol. 6. Pregnancy, breastfeeding, or unwillingness to use effective contraception during the study period. 7. Concurrent anticoagulant or antiplatelet therapy (including aspirin, clopidogrel, warfarin, or other DOACs) that cannot be safely discontinued. A washout period of at least 5 half-lives is required before randomization. 8. Use of NSAIDs, SSRIs, or other medications that significantly increase bleeding risk, unless approved by the PI with clear risk-benefit justification. 9. Active hepatocellular carcinoma (HCC) outside Milan criteria or with vascular invasion. 10. Current or planned liver transplantation.
Conditions Cancer Related Cognitive Impairment, Bre...
Phase NA
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to examine the efficacy of a novel, remotely-applied group intervention, Cognitive Retraining and Functional Treatment Group (CRAFT-G), designed to improve cognitive function, mental health and functional outcome in breast cancer survivors (BCS) with Cancer-Related Cognitive Impairment (CRCI) while simultaneously collecting data on the barriers and facilitators of implementation in clinical settings. The main question it aims to answer is: We hypothesize that participants receiving CRAFT-G will show gains in mental health, cognitive and daily function, and that the CRAFT-G benefits will endure for three months following treatment completion. Participants assigned to the waitlist control will crossover to the CRAFT-G intervention group after 6 weeks. Participants will ask to complete CRAFT-G intervention, which include: * Six remote group sessions (1.5hr each) * Between the sessions, participants will be guided to complete CRCI-specific computerized cognitive training (CCT) 3 times per week delivered using dedicated app. * Psychoeducation materials Assessment will take place in 3 time points: before intervention (frontal meeting for baseline assessment), post intervetion and 3 months post intervention. The study will be conducted to explore implementation barriers and facilitators. This will be done by endline qualitative interviews with the participants' research group.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: CRAFT-G — CRAFT-G include six remote group sessions (1.5hr each) led by an occupational therapist. The content of the meetings will be adapted from the cognitive orientation to occupational performance (CO-OP) approach accompanied with relevant psychoeducation materials. Between the sessions, participants will be guided to complete Cancer-related cognitive impairment (CRCI)-specific computerized cognitive training (CCT) 3 times per week delivered using dedicated app. In addition, psychoeducation materials will be delivered during group sessions.
  • Other: CCT — Participants opting for the cognitive training group will undergo computerized cognitive training (CCT), similar in content and duration to that provided in the CRAFT-G intervention group.

Primary Outcomes

  • Functional Assessment of Cancer Therapy - Cognition (FACT COG) (At baseline assessment and will be repeated post-intervention at week 6, and at follow-up (week 12).)
  • The Canadian Occupational Performance Measure (COPM) (At baseline assessment and will be repeated post-intervention at week 6, and at follow-up (week 12).)
  • The Performance Quality Rating Scale (PQRS) (At baseline assessment and will be repeated post-intervention at week 6, and at follow-up (week 12).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-16
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hadassah Medical Organization
Collaborators: Israel Cancer Association, Hebrew University of Jerusalem
Contact Information
Study Contact:
Chenanit Hamami
+972506373099
chenanit.hamami@mail.huji.ac.il
Chenanit Hamami, Mrs.
+972506373099
chenanit.hamami@mail.huji.ac.il
Hadassah Medical Care
Yafit Gilboa, Prof.
yafit.gilboa@mail.huji.ac.il
Hadassah Medical Care
Interventions
  • Behavioral: CRAFT-G — CRAFT-G include six remote group sessions (1.5hr each) led by an occupational therapist. The content of the meetings will be adapted from the cognitive orientation to occupational performance (CO-OP) approach accompanied with relevant psychoeducation materials. Between the sessions, participants will be guided to complete Cancer-related cognitive impairment (CRCI)-specific computerized cognitive training (CCT) 3 times per week delivered using dedicated app. In addition, psychoeducation materials will be delivered during group sessions.
  • Other: CCT — Participants opting for the cognitive training group will undergo computerized cognitive training (CCT), similar in content and duration to that provided in the CRAFT-G intervention group.
Study Locations (1 sites)
Hadassah Medical Care, Jerusalem, Israel
Eligibility Criteria
Inclusion Criteria: 1. women, 18 years old and older 2. A subjective concern about declines in cognitive functioning related to a diagnosis of breast cancer and/or cancer related treatment 3. Objective cognitive decline with no dementia (19\<MOCA) 4. 6 months or more after completion of an active treatment for cancer 5. Daily access to the internet and sufficient basic skills to operate a computer Exclusion Criteria: * Unstable psychiatric or other health condition according to participants' self-report and medical file.
Conditions Depression, Anxiety Disorders, Psychiatr...
Phase NA
Enrollment 204
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The current project aims to evaluate the extent to which psychological interventions based on Cognitive Behavioral Therapy (CBT), provided within the framework of care, may be helpful for patients in psychiatric inpatient care. The background to the project is the substantial lack of psychological treatment available to patients in psychiatric inpatient care, despite evidence suggesting that active psychological interventions can have a positive effect on psychiatric problems, such as reduced depressive symptoms, decreased anxiety, and reduced rates of readmission to inpatient psychiatric care. Previous research evaluating the effects of CBT in inpatient settings is, however, rare and more knowledge is needed both nationally and internationally. In addition to the potential direct effect of psychological treatment on patients' difficulties, there is also a high demand for such support from patients, for example, as expressed at patient forums conducted by participation coordinators in Region Stockholm, Sweden. In psychiatric outpatient and primary care, there is currently good evidence supporting CBT, and these methods are highly beneficial for both patients and practitioners. Digitalization and blended formats, with therapist-supported internet treatments, can also increase access to interventions. Studies of CBT for, for example, depression, anxiety, and psychosis are well documented and have shown a significant reduction in psychiatric symptoms as well as improved quality of life. But scarcity of studies conducted in inpatient care limits available knowledge on feasibility and effects of CBT interventions to this group of patients. This strongly motivates further systematic evaluation and research on CBT in inpatient psychiatric care, and the aim of the present study is to implement and evaluate CBT in this context. Investigators plan to test this at four to six psychiatric inpatient units and evaluate the impact of the intervention on patients' levels of activity and symptoms of low mood and depression in a randomized controlled trial. In addition, investigators wish to conduct two different interview studies with patients and staff to obtain a detailed description of how they experience the intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Cognitive Behavioral Therapy — Inpatients at the ward receives manual-based CBT during admission. The sessions are delivered by mental health professionals.
  • Other: treatment as usual (TAU) (Control Group) — Including medical treatment, other activities at the ward, offering of daily conversations (DC)

Primary Outcomes

  • Behavioral Activation Depression Scale - Short Form (BADS-SF) (Change from baseline (at admission) to discharge, up to four weeks. Follow-up will be collected three months and one year following discharge.)
  • Clinical Outcomes in Routine Evaluation - 10 (CORE-10) (Change from baseline (at admission) to discharge, up to four weeks. Follow-up will be collected three months and one year following discharge.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2028-03-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 204 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Stockholm
Collaborators: Karolinska Institutet, Stockholm University
Principal Investigators:
  • Johan Holmberg, PhD (PRINCIPAL_INVESTIGATOR) - Centre for Psychiatry Research, Region Stockholm/Karolinska Institutet
Contact Information
Study Contact:
Johan Holmberg, PhD
+46708235089
johan.holmberg.1@ki.se
Johan D Holmberg, PhD
+46708235089
johan.d.holmberg@regionstockholm.se
Centrum för psykiatriforskning, Region Stockholm
Interventions
  • Behavioral: Cognitive Behavioral Therapy — Inpatients at the ward receives manual-based CBT during admission. The sessions are delivered by mental health professionals.
  • Other: treatment as usual (TAU) (Control Group) — Including medical treatment, other activities at the ward, offering of daily conversations (DC)
Study Locations (1 sites)
Centrum för psykiatriforskning, Region Stockholm, Stockholm, 11354 Sweden
Eligibility Criteria
Inclusion Criteria: * Admitted as patient in Psychiatric Inpatient Care * Expected to remain admitted on the ward for at least 3 days * Assessed as being capable of giving consent regarding participation. * Assessed as able to engage in and complete conversations. * Sufficient level of language skills to understand the content of conversations and client material included in the intervention. Exclusion Criteria: • Other ongoing psychotherapeutic contact.